Cumberland Pharmaceuticals Inc. Revises Timing for Ifetroban Data

What Happened
Cumberland Pharmaceuticals Inc. announced via Form 8‑K (filed August 28, 2026) that long‑term safety and efficacy data from the ongoing open‑label extension of its Phase 2 FIGHT DMD trial of ifetroban will not be available as previously indicated for August 2026. The company had presented Phase 2 data on June 26, 2026 at the Parent Project Muscular Dystrophy conference in Orlando, Florida and included a slide noting an expected August 2026 update; Cumberland now says that update will be delayed and will be presented at a future date when available.

Key Details

• Filing: Form 8‑K filed August 28, 2026 (Regulation FD disclosure, Item 7.01).
• Trial: Phase 2 FIGHT DMD evaluating ifetroban for Duchenne muscular dystrophy heart disease; long‑term open‑label extension data were expected.
• Change: Company states the long‑term safety and efficacy data are not yet available and will not be presented in August 2026.
• Disclosure: The 8‑K reiterates standard forward‑looking statement cautions about risks and uncertainties.

Why It Matters
Investors tracking Cumberland’s clinical progress and upcoming data releases should note a timing change for a potentially material clinical update. The filing does not report new safety or efficacy results—only that the long‑term extension data will be delayed—so there is no new clinical information to evaluate at this time. The change may affect expectations around near‑term milestones for the ifetroban program; Cumberland says it will present the data when it becomes available.